• E-mail
• Print
• Comment
• Font Size
• Digg
• del.icio.us
• Discuss article

Cadence Pharmaceuticals' CEO Ted Schroeder to Present at the BIOCOM Investor Conference in San Diego on October 27, 2009

Posted on: Tuesday, 20 October 2009, 16:00 CDT

SAN DIEGO, Oct. 20 /PRNewswire-FirstCall/ -- Cadence Pharmaceuticals, Inc. (Nasdaq: CADX), a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates principally for use in the hospital setting, announced today that the company's President and CEO Ted Schroeder will present the company's corporate overview on Tuesday, October 27, 2009 at 10:30am Pacific Time (1:30pm Eastern Time) during the BIOCOM Investor Conference at the Hyatt Regency La Jolla Hotel in San Diego.

The presentation will be simultaneously webcast and can be accessed on Cadence Pharmaceuticals' website at www.cadencepharm.com in the Investor Relations section. A replay of the webcast will be available approximately three hours following the live webcast and will be archived for 90 days.

About Cadence Pharmaceuticals, Inc.

Cadence Pharmaceuticals is a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates principally for use in the hospital setting. The company is currently developing Acetavance(TM) (intravenous acetaminophen), its investigational product candidate for the treatment of acute pain and fever. For more information about Cadence's pipeline, visit www.cadencepharm.com.

Cadence(TM) and Acetavance(TM) are trademarks of Cadence Pharmaceuticals, Inc.

Contacts: William R. LaRue SVP, CFO Cadence Pharmaceuticals, Inc. 858-436-1400

SOURCE Cadence Pharmaceuticals, Inc.

Source: PR Newswire

More News in this Category